Growth Capitalist (https://growthcapitalist.com/tag/biomed/page/11/)
Brainstorm Cell Therapeutics (BCLI) announced a $2 million Common Stock transaction with investor ACCBT Corporation. The common stock was sold at $0.30 per share, an approximate 31% premium to the market price ($0.23) of BCLI at deal announcement. A series of 6,666,667 24-Month Warrants with an exercise price of $0.50 per share (118.34% premium) was issued to the investor in this transaction. See the PlacementTracker Deal Summary.
Synta Pharmaceuticals Corp. (SNTA) announced that it has raised $50 million in a Registered Direct transaction with investors including members of the Company's board of directors. The common stock is priced at $8.61 per share, the market price ($8.61) of SNTA at deal announcement. This transaction was completed without an agent. See the PlacementTracker Deal Summary.
ACADIA Pharmaceuticals (ACAD) announced that it has raised $84.17 million in a Common Stock transaction. The common stock was sold at $4.43 per share, an approximate 0% premium to the market price ($4.43) of ACAD at deal announcement. A series of 500,000 7-year Warrants with an exercise price of $4.43 per share (0% premium) was issued to the investors in this transaction. Cowen and Company and Jefferies & Co. acted as lead agents in the Placement with JMP Securities acting as co-agent on the transaction. The transaction is expected to close by Dec.
Aradigm Corp. (ARDM) announced that it has raised $6 million in a Common Stock transaction with investors including funds managed by First Eagle Investment Management. The common stock was sold at $0.12 per share, an approximate 9% premium to the market price ($0.11) of ARDM at deal announcement. Warrants were not disclosed. Ladenburg Thalmann & Co. acted as the exclusive agent on the transaction.
